SEPN:NASDAQSepterna, Inc. Analysis
Data as of 2026-05-26 - not real-time
$28.36
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Septerna, Inc. is trading in a clear bullish technical environment – the short‑term moving average sits above the longer‑term average, the MACD line is above its signal and the histogram remains positive, while RSI is in the upper‑mid range, indicating sustained momentum without extreme overbought pressure.
Fundamentally, the company posted a quarterly loss that beat consensus expectations, and it holds a strong cash balance relative to modest debt, yet it remains unprofitable with negative margins and a high beta, contributing to elevated volatility. Analyst consensus is strongly positive, with a "strong buy" rating and a sizable upside to analyst target prices, suggesting the market may be under‑pricing the long‑term growth story.
Fundamentally, the company posted a quarterly loss that beat consensus expectations, and it holds a strong cash balance relative to modest debt, yet it remains unprofitable with negative margins and a high beta, contributing to elevated volatility. Analyst consensus is strongly positive, with a "strong buy" rating and a sizable upside to analyst target prices, suggesting the market may be under‑pricing the long‑term growth story.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Positive technical momentum with bullish SMA crossover and MACD histogram
- Quarterly earnings beat reducing near‑term downside risk
- Increasing volume supporting price appreciation
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong cash position enabling continued R&D and partnership execution
- Analyst consensus of strong buy and implied upside to target price
- Pipeline progress, notably Phase 1 data for SEP‑631 supporting further clinical advancement
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic partnership with Novo Nordisk offering long‑term commercialization potential
- High‑growth biotech sector despite inherent regulatory risk
- Potential for significant valuation uplift if clinical milestones are met
Key Metrics & Analysis
Financial Health
Revenue Growth12011.00%
Profit Margin-49.88%
P/E Ratio-10.7
ROE-9.26%
ROA-8.49%
Debt/Equity6.10
P/B Ratio3.3
Op. Cash Flow$107.9M
Free Cash Flow$24.0M
Industry P/E27.6
Technical Analysis
TrendBullish
RSI62.7
Support$22.78
Resistance$29.89
MA 20$25.36
MA 50$24.94
MA 200$22.94
MACDBullish
VolumeIncreasing
Fear & Greed Index91.54
Valuation
Fair Value$26.14
Target Price$44.25
Upside/Downside56.03%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.28
Volatility64.01%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.